(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile. Read More
Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million. Read More
(Alliance News) - Avacta Group PLC on Wednesday said it has completed the fifth dose escalation cohort in its phase 1 clinical study of AVA6000. Read More
Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months. Read More
(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery. Read More
(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight. Read More
(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment. Read More
(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application. Read More
(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million. Read More
(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million. Read More
(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division. Read More
